Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein

Journal of Virology

Volumn 74, Issue 13, 2000, Pages 6147-6155

  Doronin, Konstantin ^a   Toth, Karoly ^a   Kuppuswamy, Mohan ^a   Ward, Peter ^a   Tollefson, Ann E ^a   Wold, William S M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS DEATH PROTEIN; BETA GALACTOSIDASE; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL CYCLE G0 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOLYSIS; FEMALE; GENE OVEREXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRUS E3 PROTEINS; ADENOVIRUSES, HUMAN; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE; CELLS, CULTURED; GENE EXPRESSION; GENETIC VECTORS; HELA CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0034086730     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.13.6147-6155.2000     Document Type: Article

References (48)

1. Barker, D. D., and A. J. Berk. 1987. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156:107-121.
2. Bett, A. J., V. Krougliak, and F. L. Graham. 1995. DNA sequence of the deletion/insertion in early region 3 of Ad5 dl309. Virus Res. 39:75-82.
3. Bilbao, G., J. L. Contreras, J. Gomez-Navarro, and D. T. Curiel. 1998. Improving adenoviral vectors for cancer gene therapy. Tumor Targeting 3: 59-79.
4. Bischoff, J. R., D. H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J. A. Nye, A. Sampson-Johannes, A. Fattaey, and F. McCormick. 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376.
5. Branton, P. E. 1999. Early gene expression, p. 39-58. In P. Seth (ed.). Adenoviruses: basic biology to gene therapy. R. G. Landes Co., Austin, Tex.
6. Chakravarti, D., V. Ogryzko, H. Y. Kao, A. Nash, H. Chen, Y. Nakatani, and R. M. Evans. 1999. A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell 96:393-403.
7. Chroboczek, J., F. Bieber, and B. Jacrot. 1992. The sequence of the genome of adenovirus type 5 and its comparison with the genome of adenovirus type 2. Virology 186:280-285.
8. Crystal, R. G. 1999. In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors. Cancer Chemother. Pharm. 43(Suppl.):S90-S99.
9. Flint, J., and T. Shenk. 1997. Viral transactivating proteins. Annu. Rev. Genet. 31:177-212.
10. Freytag, S. O., K. R. Rogulski, D. L. Paielli, J. D. Gilbert, and J. H. Kim. 1998. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 9: 1323-1333.
11. Goodrum, F. D., and D. A. Ornelles. 1998. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol. 72: 9479-9490.
12. Hall, A. R., B. R. Dix, S. J. O'Carroll, and A. W. Braithwaite. 1998. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat. Med. 4:1068-1072.
13. Hallenbeck, P. L., Y.-N. Chang, C. Hay, D. Golightly, D. Stewart, J. Lin, S. Phipps, and Y. L. Chiang. 1999. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther. 10:1721-1733.
14. Hamamori, Y., V. Sartorelli, V. Ogryzko, P. L. Puri, H. Y. Wu, J. Y. Wang, Y. Nakatani, and L. Kedes. 1999. Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A. Cell 96:405-413.
15. Harada, J. N., and A. J. Berk. 1999. p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol. 73:5333-5344.
16. Harlow, E., B. R. J. Franza, and C. Schley. 1985. Monoclonal antibodies specific for adenovirus early region 1A proteins: extensive heterogeneity in early region 1A products. J. Virol. 55:533-546.
17. Haussman, J., D. Ortmann, M. Witt, M. Veit, and W. Seidel. 1998. Adenovirus death protein, a transmembrane protein encoded in the E3 region, is palmitoylated at the cytoplasmic tail. Virology 244:343-351.
18. Hay, J. G., N. Shapiro, H. Sauthoff, S. Heitner, W. Phupakdi, and W. N. Rom. 1999. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene. Hum. Gene Ther. 10:579-590.
19. Heise, C., A. Sampson-Johannes, A. Williams, F. McCormick, D. D. Von Hoff, and D. H. Kirn. 1997. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeulic agents. Nat. Med. 3:639-645.
20. Heise, C. C., A. M. Williams, S. Xue, M. Propst, and D. H. Kirn. 1999. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 59:2623-2628.
21. Horwitz, M. S. 1996. Adenoviruses, p. 2149-2171. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology. Lippincott-Raven Publishers, Philadelphia, Pa.
22. Howe, J. A., J. S. Mymryk, C. Egan, P. E. Branton, and S. T. Bayley. 1990. Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis. Proc. Natl. Acad. Sci. USA 87:5883-5887.
23. Jones, N., and T. Shenk. 1979. Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. Cell 17: 683-689.
24. Kirn, D., T. W. Hermiston, and F. McCormick. 1998. ONYX-015: clinical data are encouraging. Nat. Med. 4:1341-1342.
25. Kirn, D. H. 1999. Development of an E1B, 55 kDa gene-deleted, selectively replicating adenovirus for the treatment of cancer: ONYX-015, p. 201-206. In P. Seth (ed.), Adenoviruses: basic biology to gene therapy. R. G. Landes Co., Austin, Tex.
26. Mahr, J. A., and L. R. Gooding. 1999. Immune evasion by adenoviruses. Immunol. Rev. 168:121-130.
27. Martin, M. E., and A. J. Berk. 1999. Corepressor required for adenovirus E1B 55,000-molecular-weight protein repression of basal transcription. Mol. Cell. Biol. 19:3403-3414.
28. Montell, C., G. Courtois, C. Eng, and A. Berk. 1984. Complete transformation by adenovirus 2 requires both E1A proteins. Cell 36:951-961.
29. Prives, C. 1998. Signaling to p53: breaking the MDM2-p53 circuit. Cell 95: 5-8.
30. Rodriguez, R., E. R. Schuur, H. Y. Lim, G. A. Henderson, J. W. Simons, and D. R. Henderson. 1997. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57:2559-2563.
31. Rothmann, T., A. Hengstermann, N. J. Whitaker, M. Scheffner, and H. zur Hausen. 1998. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72:9470-9478.
32. Scaria, A., A. E. Tollefson, S. K. Saha, and W. S. M. Wold. 1992. The E3-11.6K protein of adenovirus is an Asn-glycosylated integral membrane protein that localizes to the nuclear membrane. Virology 191:743-753.
33. Seth, P., Y. Katayose, and A. N. S. Rakkar. 1999. Adenoviral vectors for cancer gene therapy, p. 103-120. In P. Seth (ed.), Adenoviruses: basic biology to gene therapy. R. G. Landes Co., Austin, Tex.
34. Shinoura, N., Y. Yoshida, R. Tsunoda, M. Ohashi, W. Zhang, A. Asai, T. Kirino, and H. Hamada. 1999. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. Cancer Res. 59:3411-3416.
35. Thimmappaya, B., C. Weinberger, R. J. Schneider, and T. Shenk. 1982. Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection. Cell 31:543-551.
36. Tollefson, A. E., T. W. Hermiston, and W. S. M. Wold. 1998. Preparation and titration of CsCl-handed adenovirus stocks, p. 1-9. In W. S. M. Wold (ed.), Adenovirus methods and protocols. Humana Press, Inc., Totowa, N.J.
37. Tollefson, A. E., J. S. Ryerse, A. Scaria, T. W. Hermiston, and W. S. M. Wold. 1996. The E3-11.6kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology 220:152-162.
38. Tollefson, A. E., A. Scaria, T. W. Hermiston, J. S. Ryerse, L. J. Wold, and W. S. M. Wold. 1996. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol. 70:2296-2306.
39. Tollefson, A. E., A. Scaria, S. K. Saha, and W. S. M. Wold. 1992. The 11,600-MW protein encoded by region E3 of adenovirus is expressed early but is greatly amplified at late stages of infection. J. Virol. 66:3633-3642.
40. Turnell, A. S., R. J. Grand, and P. H. Gallimore. 1999. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J. Virol. 73:2074-2083.
41. White, E. 1998. Regulation of apoptosis by adenovirus E1A and E1B oncogenes. Semin. Virol. 8:505-513.
42. Wildner, O., R. M. Blaese, and J. C. Morris. 1999. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. 59:410-413.
43. Wildner, O., J. C. Morris, N. N. Vahanian, H. J. Ford, W. J. Ramsey, and R. M. Blaese. 1999. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther. 6:57-62.
44. Wold, W. S. M., and G. Chinnadurai. 2000. Adenovirus proteins that regulate apoptosis, p. 200-232. In A. J. Cann (ed.), DNA virus replication. Oxford University Press, Oxford, United Kingdom.
45. Wold, W. S. M., and A. E. Tollefson. 1999. Adenovirus-host interactions to subvert the host immune system, p. 243-250. In P. Seth (ed.), Adenoviruses: basic biology to gene therapy. R. G. Landes Co., Austin, Tex.
46. Wold, W. S. M., K. Doronin, K. Toth, M. Kuppuswamy, D. L. Lichtenstein, and A. E. Tollefson. 1999. Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr. Opin. Immunol. 11: 380-386.
47. Wold, W. S. M., and A. E. Tollefson. 1998. Adenovirus E3 proteins: 14.7K, RID, and gp19K inhibit immune-induced cell death; adenovirus death protein promotes cell death. Semin. Virol. 8:515-523.
48. Yu, D.-C., Y. Chen, M. Seng, J. Dilley, and D. R. Henderson. 1999. The addition of adenovirus type 5 region E3 enables Calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 59:4200-4203.